Brand Intelligence Graph
Company Overview
About eGenesis
eGenesis is developing gene-edited pig organs for human transplantation — xenotransplantation — using a 69-gene CRISPR editing protocol that simultaneously knocks out pig genes that trigger human rejection, adds human immune tolerance genes, and eliminates porcine endogenous retroviruses. The company received FDA clearance for its IND for EIGEN-2784 (a gene-edited pig kidney) for end-stage kidney disease, and its first transplant patient remained dialysis-free at more than 7 months post-transplant — the longest reported survival for a xenotransplantation recipient.
Business Model & Competitive Advantage
The 69-gene edit represents the most complex CRISPR modification ever applied to a large animal, developed over a decade of research at Harvard Medical School. The clinical trial now enrolling is pivotal: if positive results are sustained, it would establish gene-edited pig kidneys as a viable alternative to human donor organs — addressing the chronic shortage of 100,000+ patients on the US kidney transplant waiting list, of whom 13 patients die each day awaiting a kidney.
Competitive Landscape 2025–2026
eGenesis's approach is systematically addressing the three barriers to xenotransplantation: hyperacute rejection (pig galactose antigens), chronic rejection (human immune response), and the risk of porcine viral transmission (PERV elimination). The 69-gene protocol represents the most thorough published solution to all three barriers simultaneously, making eGenesis the most clinically advanced xenotransplantation program globally.
Key Differentiators
Emerging Innovator
eGenesis is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Florence Healthcare
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to stre
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare eGenesis with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from eGenesis? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim eGenesis Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention eGenesis vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →